Filed Under News
CANTON, Mass., /PRNewswire/ — organogenesis, Inc., a leading regenerative medicine company, has just been named the recipient of two prestigious awards honoring the company’s cutting edge development, manufacturing and economic impact.
Organogenesis’ manufacturing division has been named 2008 “Team of the Year” by Pharmaceutical Manufacturing, a prominent industry publication. The “Team of the Year” honor will be highlighted in the magazine’s upcoming December 2008 issue. Additionally, the company was honored by the Massachusetts Alliance for Economic Development as the Silver winner of its Fifth Annual Team Massachusetts Economic Impact Award, presented at a November 25th awards event.
Organogenesis was the first company to successfully mass produce living regenerative medicine products — reaching hundreds of thousands of patients in the U.S. and around the world. Its signature product, Apligraf(R), is the first living cell therapy to have received U.S. Food and Drug Administration (FDA) approvals to close both diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).
“We are honored to receive national and state recognition of the company’s vision, its ingenuity and hard work,” said Geoff MacKay, CEO of organogenesis. “Organogenesis is committed to bringing the promise of regenerative medicine into everyday medical care. To have our efforts and hard work recognized in this way is very gratifying for the company and our employees.”
MacKay continued, “The intricate processes required to mass produce a living cell therapy product require a great deal of innovation and dedication, and our top-notch manufacturing group hits its target every day. This team is in large part responsible for the quality, the growth and the contribution that marks organogenesis as a regenerative medicine leader in Massachusetts and around the world.”